Clinical trial
Safety and Effectiveness of a Combination Anti-HIV Drug Treatment
NCT00005018 · Glaxo Wellcome, Industry · Completed
Key facts
| NCT number | NCT00005018 |
|---|---|
| Title | Safety and Effectiveness of a Combination Anti-HIV Drug Treatment |
| Official title | A Phase IV 48-Week, Randomized, Open-Label, Multicenter Trial of Abacavir (300mg BID)/Efavirenz (600mg QD)/Didanosine (400mg QD) +/- Hydroxyurea (500mg BID) in HIV-1 Infected Subjects Failing Initial Therapy With 3TC/ZDV (or d4T) +/- Protease Inhibitor(s) |
| Lead sponsor | Glaxo Wellcome, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Hydroxyurea, Abacavir sulfate, Efavirenz, Didanosine |
| Enrollment | 150 |
| Start date | Jul 1, 1999 |
| Completion | Oct 1, 2000 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: